Digital health just scored a decisive victory. Fitterfly, the pioneering digital therapeutics arm of PB Health, secured a crucial Government of India patent. This patent protects its proprietary Personalised Glycemic Response (PGR) technology. The move cements Fitterfly’s dominant position. It dramatically alters the future of chronic disease management in India.
AI Engine Powers Precision Care
The patent covers the core of Fitterfly’s diabetes program. This AI-led engine is the PGR technology. It allows data-driven care at massive scale. PGR helps millions manage diabetes better. It predicts how specific foods and activities impact blood sugar. It makes this prediction up to three hours in advance.
This prediction power is a game-changer. It removes the daily burden of food decisions for patients. PGR moves far beyond standard, generic advice.
The model boasts a huge training dataset. It analysed over 10 lakh (1 million) Continuous Glucose Monitoring (CGM) data points. It studied over 1.21 lakh individual meals. The algorithm factors in every critical metric. These include age, BMI, heart rate, sleep, and co-morbidities. This process delivers highly accurate, personalised glucose predictions.
Clinical Outcomes Prove Efficacy
The technology already boasts unmistakable clinical success. Over 40,000 members have benefited from the PGR-powered programs. The results are clinically significant, matching high-grade pharmaceutical interventions.
In 2025, 94% of members with very high baseline HbA1c levels (above 9%) saw massive improvement. They recorded an average reduction of 2.8 points within 6 to 12 months. This outcome is comparable to standard multi-drug regimens.
Furthermore, Fitterfly’s data confirms that diabetes remission is possible. It applies to a large number of Type 2 Diabetes cases, particularly in the early stages. The program also delivers holistic health gains. Members improved critical markers. These include reduced serum cholesterol, lower triglycerides, and better blood pressure control. This success transforms patients’ quality of life. It substantially reduces future complication risks.
Dr. Vineet Nair, Head of Program Design at Fitterfly, affirmed the approach. “PGR helps us go beyond standard protocols,” he said. “It delivers care that adapts to each member’s data. This drives better adherence. It guarantees improved glucose control and more consistent progress.”
Patent Builds a Commercial Fortress
The patent acquisition is a legal triumph. It gives Fitterfly a formidable fortress of Intellectual Property (IP).
The Government of India approval confirms the unique nature of the PGR algorithm. It grants Fitterfly exclusive commercial rights. This protection shields the company from direct competition. It also exponentially increases PB Health’s valuation. The technology shifts from a service model to a protected, scalable asset.
Dr. Arbinder Singal, Head of Preventive and Digital Health at PB Health and Co-founder at Fitterfly, emphasized the strategic importance. “Our proven outcomes and proprietary technology add significant value,” he stated. “The patent secures the technical core of our chronic disease management offering.”
The move reinforces PB Health’s vision. They aim to create a tech-first, integrated healthcare ecosystem. Fitterfly’s digital expertise becomes the crucial preventative arm. This balances PB Health’s growing hospital network in the Delhi-NCR region.
India’s Health System Faces Transformation
Chronic conditions devastate India’s population. Nearly 40 percent of Indian adults suffer from diabetes, hypertension, or obesity. This is an immense, growing crisis.
Technology like PGR offers the only viable path to scale positive change. It empowers patients, doctors, and insurers alike.
For Insurers: Diabetes remains the biggest cost driver. Fitterfly’s outcome-led programs offer a clear solution. They reduce the risk of progression and expensive hospitalizations. Several leading insurance companies already recognize this shift. They integrate Fitterfly’s programs into their policyholder ecosystem. This acts as a proactive risk management measure. It lowers long-term claims.
For Patients: PGR grants control. It is a fundamental shift from reactive treatment. It establishes continuous, outcome-led management. This approach improves long-term disease stability. It leads to huge cost savings and boosts work productivity.
Dr. Singal added, “We are working closely with leading insurers. We are shifting the focus from treatment to long-term health stability. This is a crucial step. It builds a more sustainable, future-ready healthcare model for India.”
The successful patenting of PGR technology marks a definitive moment. It confirms that Digital Therapeutics (DTx) is not a supplement. DTx is becoming the first line of defence against India’s escalating chronic disease epidemic. This victory is a resounding signal. Personalised, AI-driven healthcare is now locked in. It is set to dominate the market.